The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -8.90 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2025, as Spero Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Collaboration Revenue Related Party$47.0M
- Collaboration Revenue$12.6M
- Grant$7.2M
- Grant Revenue$7.2M
- SPR Two Zero Six$100K
Leadership changes
From Spero Therapeutics, Inc.'s own filings, the day they're filed.
- Satyavrat Shukla · Chief Executive Officer · departureeff. 2025-05-02
- Tamara Joseph · Chief Legal Officer · departureeff. 2024-03-06
- Sath Shukla · departureeff. 2024-03-06
Latest filings
- 8-K · Company announcement2026-05-13
- 10-Q · Quarterly report2026-05-13
- DEF 14A · Annual proxy (pay & governance)2026-04-27
- 10-K · Annual report2026-03-26
- 8-K · Company announcement2026-03-26
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Spero Therapeutics, Inc., every answer cited🔒
- The Intelligence Brief — added when Spero Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.